Abbreviated New Drug Application

Perrigo Confirms First to File Patent Challenge for Generic Version of Testosterone Gel 1.62%

Perrigo Co. (Nasdaq: PRGO) announced that it has filed with the U.S. Food and Drug Administration an Abbreviated New Drug Application for testosterone gel 1.62 percent and that it has notified AbbVie Inc., the owner of the Reference Listed Drug of its filing.

WWJ Newsradio 950–2013/02/19

Perrigo Announces FDA Final Approval Of Betamethasone Valerate Foam

Perrigo Co. (Nasdaq: PRGO) Tuesday announced that its partner, Cobrek Pharmaceuticals Inc., received final approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for betamethasone valerate foam 0.12 percent, the generic equivalent of Luxiq Foam.

WWJ Newsradio 950–2012/11/27

Perrigo Files For Generic Astepro Nasal Spray, Patent Lawsuit

Perrigo Co. (Nasdaq: PRGO) announced that it has filed with the United States Food and Drug Administration an Abbreviated New Drug Application for azelastine hydrochloride nasal spray (0.15%) and has notified Meda Pharmaceuticals Inc., the owner of the New Drug Application of its filing.

WWJ Newsradio 950–2012/01/23

Listen Live!